Table 1.

Study population

	HL (n = 52)	NHL (n = 57)	No lymphoma (n = 228)
Male sex	62%	72%	61%
Age	40 ± 15	50 ± 17	64 ± 13	***	###	+++
BMI (kg/m2)	25.11 ± 5.01	25.99 ± 7.67	25.88 ± 4.64
Prior chemotherapy	98%	93%	36%		###	+++
Doxorubicin dose (mg/m2)	179 ± 143	220 ± 113	NA
Prior radiotherapy	23%	40%	57%		###
Serum glucose levels (mmol/L)	5.6 ± 1.7	5.4 ± 1.1	6.0 ± 1.3			++
Diabetes mellitus	6%	12%	16%
Serum creatinine levels (μmol/L)	72 ± 22	72 ± 18	79 ± 31
Glomerular filtration rate (mL/min * 1.73 m2)	111 ± 18	101 ± 20	85 ± 20		###	+++
Increased TSH (>4.0 mU/L)	4.3%	11.5%	24.3%		#

BMI, body mass index; HL, Hodgkin's lymphoma; NHL, non‐Hodgkin's lymphoma; TSH, thyroid‐stimulating hormone.

Continuous data are reported as mean ± standard deviation. Count data are reported as percentages. Statistics: Tukey's honest significance test was used for continuous data, and Yates's χ ² test was used for count data applying Holm's method for P‐value adjustment.

^* P < 0.05 (HL vs. NHL).

^** P < 0.01 (HL vs. NHL).

^*** P < 0.001 (HL vs. NHL).

^# P < 0.05 (HL vs. no lymphoma).

^## P < 0.01 (HL vs. no lymphoma).

^### P < 0.001 (HL vs. no lymphoma).

⁺ P < 0.05 (NHL vs. no lymphoma).

⁺⁺ P < 0.01 (NHL vs. no lymphoma).

⁺⁺⁺ P < 0.001 (NHL vs. no lymphoma).